Edwards Lifesciences (EWL) Stock Statistics & Valuation Metrics
Total Valuation
Edwards Lifesciences has a market cap or net worth of EUR 47.82B. The enterprise value is EUR 48.81B.
- Market Cap
- EUR 47.82B
- Enterprise Value
- EUR 48.81B
Share Statistics
Edwards Lifesciences has 576,400,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 576,400,000
- Owned by Insiders
- 0.20%
- Owned by Institutions
- 56.08%
Financial Efficiency
Edwards Lifesciences’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 11.40%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 11.40%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 379.23K
- Profits Per Employee
- 67.09K
- Employee Count
- 16,000
- Asset Turnover
- 0.44
- Inventory Turnover
- 1.18
Valuation Ratios
The current PE Ratio of Edwards Lifesciences is 54.71. Edwards Lifesciences’s PEG ratio is -0.73.
- PE Ratio
- 54.71
- PS Ratio
- 8.43
- PB Ratio
- 5.17
- Price to FCF
- 38.27
- Price to Operating Cash Flow
- 31.89
- PEG Ratio
- -0.73
Income Statement
In the last 12 months, Edwards Lifesciences had revenue of 6.07B and earned 1.07B in profits. Earnings per share was 1.84.
- Revenue
- 6.07B
- Gross Profit
- 4.74B
- Operating Income
- 1.64B
- Pretax Income
- 1.27B
- Net Income
- 1.07B
- EBITDA
- 1.43B
- Earnings Per Share (EPS)
- 1.84
Cash Flow
In the last 12 months, operating cash flow was 1.72B and capital expenditures -286.70M, giving a free cash flow of 1.43B billion.
- Operating Cash Flow
- 1.72B
- Free Cash Flow
- 1.43B
- Free Cash Flow per Share
- 2.49
Dividends & Yields
Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.61%
- Earnings Yield
- 1.83%
Stock Price Statistics
- Beta
- 0.41
- 52-Week Price Change
- 19.40%
- 50-Day Moving Average
- 77.36
- 200-Day Moving Average
- 73.99
- Relative Strength Index (RSI)
- 74.27
- Average Volume (3m)
- 73
Important Dates
Edwards Lifesciences upcoming earnings date is Jan 27, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Jan 27, 2027
- Ex-Dividend Date
- ―
Financial Position
Edwards Lifesciences as a current ratio of 3.72, with Debt / Equity ratio of 6.82%
- Current Ratio
- 3.72
- Quick Ratio
- 3.09
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -1.56
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Edwards Lifesciences has paid 216.90M in taxes.
- Income Tax
- 216.90M
- Effective Tax Rate
- 0.17
Enterprise Valuation
Edwards Lifesciences EV to EBITDA ratio is 33.34, with an EV/FCF ratio of 36.81.
- EV to Sales
- 8.10
- EV to EBITDA
- 33.34
- EV to Free Cash Flow
- 36.81
- EV to Operating Cash Flow
- 30.68
Balance Sheet
Edwards Lifesciences has EUR 4.25B in cash and marketable securities with EUR 704.40M in debt, giving a net cash position of EUR 3.55B billion.
- Cash & Marketable Securities
- EUR 4.25B
- Total Debt
- EUR 704.40M
- Net Cash
- EUR 3.55B
- Net Cash Per Share
- EUR 6.16
- Tangible Book Value Per Share
- EUR 12.82
Margins
Gross margin is 77.98%, with operating margin of 28.09%, and net profit margin of 15.43%.
- Gross Margin
- 77.98%
- Operating Margin
- 28.09%
- Pretax Margin
- 21.77%
- Net Profit Margin
- 15.43%
- EBITDA Margin
- 24.30%
- EBIT Margin
- 21.76%
Analyst Forecast
The average price target for Edwards Lifesciences is EUR 94.30, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 94.30
- Price Target Upside
- 10.21% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 13
- Revenue Growth Forecast
- 6.85%
- EPS Growth Forecast
- 6.20%
Scores
- Smart Score
- 10
- AI Score
- ―
